All AbMole products are for research use only, cannot be used for human consumption.
ASP3026 is a potent ALK (Anaplastic Lymphoma Kinase) inhibitor. ASP3026 inhibited ALK kinase activity and was more selective than crizotinib in a Tyr-kinase panel. In an anchorage independent in vitro cell growth assay, ASP3026 inhibited the growth of NCI-H2228, a human NSCLC tumor cell line endogenously expressing EML4-ALK variant 3 and that of 3T3 cells expressing EML4-ALK variant 1, 2 and 3. The plasma and tumor concentrations of ASP3026 in mice xenografted with NCI-H2228 tumor were determined using high-performance liquid chromatography-tandem mass spectrometry. ASP3026 showed potent anti-tumor effects while crizotinib was ineffective even at 100 mg/gk qd in an EML4-ALK driven tumor model with gatekeeper mutation.
Chem Biol Interact. 2023 Apr 26;379:110516.
ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells
ASP3026 purchased from AbMole
 |
Source | Oncotarget (2014). Figure 2. ASP3026 |
| Method | apoptosis assay | |
| Cell Lines | lymphoma cells | |
| Concentrations | 0.5, 1.5, and 2.5 μM | |
| Incubation Time | 48 h | |
| Results | The occurrence of apoptosis after treatment with ASP3026 was biochemically supported by cleavage of caspase 3 and PARP |
| Cell Experiment | |
|---|---|
| Cell lines | NPM-ALK+ ALCL cells Karpas 299, SR-786 and SU-DHL-1 cells |
| Preparation method | MTS assay Cell viability was measured using MTS reagent (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; Promega, Madison, WI). Briefly, 1 × 105 cells were seeded into 96-well plates, and 20 μL of MTS reagent was added to each well and incubated for approximately 2 h at 37°C in 5% CO2. Plates were read at 490 nm. |
| Concentrations | 0.1, 0.5 and 1 μ M |
| Incubation time | 48 or 72 h |
| Animal Experiment | |
|---|---|
| Animal models | Systemic xenograft NPM-ALK+ ALCL model |
| Formulation | 0.5% methylcellulose |
| Dosages | 30 mg/kg daily for 12 weeks |
| Administration | oral gavage |
| Molecular Weight | 580.76 |
| Formula | C29H40N8O3S |
| CAS Number | 1097917-15-1 |
| Solubility (25°C) | DMSO 12 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related ALK Products |
|---|
| F-1
F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50 values of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively. |
| TL13-22
TL13-22 is a negative control for TL13-12 and a potent ALK inhibitor with an IC50 of 0.54 nM. |
| TL13-110
TL13-110 is a negative control for TL13-112 and a potent ALK inhibitor with an IC50 of 0.34 nM. |
| ALK inhibitor 2
ALK inhibitor 2 is a potent pyrimidin ALK inhibitor. |
| NVL-655 TFA
NVL-655 (ALK-IN-27) TFA is a novel, brain-permeable, selective ALK inhibitor with antitumor activity. For Ba/F3 CLIP1-LTK cells, NVL-655 (ALK-IN-27) TFA has an IC50 of 2.7 nM. It can be used in studies related to ALK-positive non-small cell lung cancer (NSCLC). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
